Charles River's Q3: DSA Volume and Divestiture Mix Lift Margins, Guidance Raised

The quarter in numbers

Charles River Laboratories reported third-quarter revenue of $982.7 million for the period ended September 26, 2026. That is a 2.2% decline from $1,004.9 million a year earlier, which the company attributed primarily to the May 2026 divestitures. Organic revenue, which excludes acquisitions, divestitures and currency, grew 4.7%. The company said this beat its prior outlook and marked a second consecutive quarter of organic growth.

Non-GAAP earnings per share were $3.09, up 27.2% from $2.43. Non-GAAP net income was $150.1 million, up 24.8% from $120.3 million. The company said the gains came mainly from a higher operating margin and a lower tax rate.

GAAP results flattered by a tax reversal

GAAP EPS of $6.86 compares with $1.10 a year ago, and GAAP net income available to common shareholders was $333.1 million versus $54.4 million. The company said the comparison includes a benefit of $245.6 million, or $5.06 per share, from reversing acquired tax reserves after newly enacted tax legislation and completion of certain tax requirements in a foreign jurisdiction.

GAAP operating margin rose to 20.6% from 13.3%, a 730 basis point increase. The company tied that primarily to a $44.6 million benefit in the DSA segment from reversing acquired non-income tax reserves. The non-GAAP figures are the cleaner read on operations.

Segments: DSA and Manufacturing carry growth

Discovery and Safety Assessment (DSA) revenue was $596.3 million, down 0.7% from $600.7 million on the divestiture of certain European Discovery Services sites. Organic revenue rose 5.9%, driven primarily by higher study volume for regulated safety assessment services. Non-GAAP operating margin improved to 26.8% from 25.4%, helped by operating leverage on that volume and lower sourcing costs for large research models. CEO Birgit Girshick said DSA net bookings and proposals continued to show robust year-over-year increases; the release gives no figures.

Manufacturing Solutions revenue was $178.9 million, down 6.2% from $190.7 million on the CDMO divestiture. Organic revenue grew 7.4% on strong demand in Biologics Testing Solutions and Microbial Solutions. Non-GAAP operating margin jumped to 38.6% from 26.7%, which the company attributed primarily to the benefit of the CDMO divestiture.

Research Models and Services (RMS) was the soft spot. Revenue was $207.5 million, down 2.8% from $213.5 million on the Cell Solutions divestiture, and organic revenue fell 0.6%. Lower small research model revenue in North America and lower large research model revenue were partly offset by higher small model revenue in China and growth in research model services, particularly Insourcing Solutions. Non-GAAP operating margin slipped to 24.4% from 25.0% on unfavorable geographic and large-model revenue mix.

Margins: portfolio reshaping plus volume

Consolidated non-GAAP operating margin rose to 23.0% from 19.7%. The company credited the CDMO divestiture and operating leverage from higher safety assessment volume. The release attributes the improvement to portfolio changes as well as underlying volume leverage, so readers should weigh both when assessing how durable the gain is.

Guidance raised

The company raised 2026 guidance, last updated August 5, 2026, citing third-quarter outperformance led by DSA and a lower tax rate. Organic revenue growth is now at least +1.5%, versus 0.0% to 1.0% before. Reported revenue is guided to (2.0)% to (1.5)%, versus (3.5)% to (2.5)%. The guidance bridge still includes a roughly 4.5% divestiture impact and a 0.5% to 1.0% favorable currency effect.

Non-GAAP EPS guidance is $11.35 to $11.55, from $11.15 to $11.45, a $0.15 increase at the midpoint. GAAP EPS guidance moves to $8.15 to $8.35 from $3.05 to $3.35, largely because of a ($5.03) per-share adjustment for the tax reserve reversal. Restructuring and efficiency costs in the bridge rise to about $1.50 per share from about $1.20, and acquisition-related amortization falls to about $2.10 from about $2.30.

Strategy, scientific and regulatory items; what to watch

The company unveiled its Pathway to Purpose strategy and Create the Future initiative at its 2026 Investor Day, and described automation steps: an automated Endosafe cartridge manufacturing suite and Apollo Orchestrate, developed with Autolomous, for digitizing lab workflows. On the regulatory front, it announced an industry collaboration with the FDA to validate preclinical screening tools that quantify and rank new drugs' abuse potential. It also introduced a rapid cell banking program in Biologics Testing Solutions, and said its Virtual Control Group database will be used in an upcoming GLP-compliant safety study for Ipsen.

Watch whether DSA bookings strength converts into revenue, as that segment drove the guidance raise. Also watch whether RMS organic revenue returns to growth, and how much non-GAAP margin gains persist once the divestiture benefit is in the base. Restructuring costs, which the guidance bridge raises, are another item to track.